BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 11904790)

  • 1. The autologous blood and marrow transplant long-term follow-up clinic: a model of care for following and treating survivors of autotransplant.
    Schimmer AD; Dranitsaris G; Ali V; Falconer M; Keating A
    Support Care Cancer; 2002 Apr; 10(3):247-52. PubMed ID: 11904790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin's lymphoma.
    Brown JR; Yeckes H; Friedberg JW; Neuberg D; Kim H; Nadler LM; Freedman AS
    J Clin Oncol; 2005 Apr; 23(10):2208-14. PubMed ID: 15753460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: a 16-year follow-up study.
    Sacchi S; Marcheselli L; Bari A; Marcheselli R; Pozzi S; Luminari S; Lombardo M; Buda G; Lazzaro A; Gobbi PG; Stelitano C; Morabito F; Quarta G; Brugiatelli M
    Haematologica; 2008 Mar; 93(3):398-404. PubMed ID: 18268277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quality of life in patients surviving at least 12 months following high dose chemotherapy with autologous bone marrow support.
    Winer EP; Lindley C; Hardee M; Sawyer WT; Brunatti C; Borstelmann NA; Peters W
    Psychooncology; 1999; 8(2):167-76. PubMed ID: 10335560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical outcomes of patients with impaired left ventricular ejection fraction undergoing autologous bone marrow transplantation: can we safely transplant patients with impaired ejection fraction?
    Tang WH; Thomas S; Kalaycio M; Sobecks R; Andresen S; Jarvis J; Rybicki L; Pohlman B; Francis GS; Bolwell BJ
    Bone Marrow Transplant; 2004 Oct; 34(7):603-7. PubMed ID: 15258558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autologous hematopoietic cell transplantation non-Hodgkin's lymphoma: 100 month follow-up.
    Bolwell B; Kalaycio M; Sobecks R; Andresen S; Mcbee M; Kuczkowski L; Rybicki L; Pohlman B
    Bone Marrow Transplant; 2002 Apr; 29(8):673-9. PubMed ID: 12180112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term follow-up after autologous hematopoietic stem cell transplantation for low-grade non-Hodgkin lymphoma.
    Laudi N; Arora M; Burns LJ; Miller JS; McGlave PB; Barker JN; Ramsay NK; Orchard PJ; Macmillan ML; Weisdorf DJ
    Biol Blood Marrow Transplant; 2005 Feb; 11(2):129-35. PubMed ID: 15682074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose intensification with autologous stem cell transplantation in relapsed and resistant Hodgkin's disease.
    Anselmo AP; Cavalieri E; Meloni G; Alimena G; Cantonetti M; Maurizi Enrici R; Tosti ME; Falchetto Osti M; Gianfelici V; Mandelli F
    Haematologica; 2002 May; 87(5):507-11. PubMed ID: 12010664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Different patterns of relapse after autologous peripheral blood stem cell transplantation in multiple myeloma: clinical results of 280 cases from the Spanish Registry.
    Alegre A; Granda A; Martínez-Chamorro C; Díaz-Mediavilla J; Martínez R; García-Laraña J; Lahuerta JJ; Sureda A; Bladé J; de la Rubia J; Fernández-Rañada JM; San Miguel J; ; ;
    Haematologica; 2002 Jun; 87(6):609-14. PubMed ID: 12031917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic outcomes of breast cancer survivorship: CALGB study 79804.
    Hensley ML; Dowell J; Herndon JE; Winer E; Stark N; Weeks JC; Paskett E
    Breast Cancer Res Treat; 2005 May; 91(2):153-61. PubMed ID: 15868443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autologous transplantation in patients with relapsed or high-grade follicular lymphoma provides long term disease-free survival and best median duration of response.
    Ganguly S; Divine CL; Deauna-Limayo D; Bodensteiner DC; Cook JD; Lewis JN; Skikne BS
    Ann Hematol; 2005 Aug; 84(8):526-31. PubMed ID: 15915350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 'Relative' chemotherapy sensitivity: the impact of number of salvage regimens prior to autologous stem cell transplant for relapsed and refractory aggressive non-Hodgkin's lymphoma.
    Chen CI; Roitman D; Tsang R; Stewart AK; Keating A; Crump M
    Bone Marrow Transplant; 2002 Dec; 30(12):885-91. PubMed ID: 12476281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma.
    Majhail NS; Weisdorf DJ; Defor TE; Miller JS; McGlave PB; Slungaard A; Arora M; Ramsay NK; Orchard PJ; MacMillan ML; Burns LJ
    Biol Blood Marrow Transplant; 2006 Oct; 12(10):1065-72. PubMed ID: 17084370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose carmustine, etoposide, and cisplatin for autologous stem cell transplantation with or without involved-field radiation for relapsed/refractory lymphoma: an effective regimen with low morbidity and mortality.
    Wadhwa PD; Fu P; Koc ON; Cooper BW; Fox RM; Creger RJ; Bajor DL; Bedi T; Laughlin MJ; Payne J; Gerson SL; Lazarus HM
    Biol Blood Marrow Transplant; 2005 Jan; 11(1):13-22. PubMed ID: 15625540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estimating late adverse events using competing risks after autologous stem-cell transplantation in aggressive non-Hodgkin lymphoma patients.
    Ruiz-Soto R; Sergent G; Gisselbrecht C; Larghero J; Ertault M; Hennequin C; Manson J; de Kerviler E; Briere J; Mounier N
    Cancer; 2005 Dec; 104(12):2735-42. PubMed ID: 16284986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [High dose chemoradiotherapy with autologous hemotopoietic stem cell transplantation for treatment of patients with advanced Hodgkin's lymphoma: a report of 11 cases].
    Zhou SY; Shi YK; He XH; Han XH; Liu P; Yang JL; Zhou AP; Feng FY
    Ai Zheng; 2002 Apr; 21(4):405-8. PubMed ID: 12452021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of autologous bone marrow transplantation in patients with relapsed non-Hodgkin's lymphoma.
    Messori A; Bonistalli L; Costantini M; Alterini R
    Bone Marrow Transplant; 1997 Feb; 19(3):275-81. PubMed ID: 9028558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Late non-relapse mortality among adult autologous stem cell transplant recipients: a nation-wide analysis of 1,482 patients transplanted in 1990-2003.
    Jantunen E; Itälä M; Siitonen T; Koivunen E; Leppä S; Juvonen E; Kuittinen O; Lehtinen T; Koistinen P; Nyman H; Nousiainen T; Volin L; Remes K
    Eur J Haematol; 2006 Aug; 77(2):114-9. PubMed ID: 16856906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term follow-up of patients with non-Hodgkin lymphoma following myeloablative therapy and autologous transplantation of CD34+-selected peripheral blood progenitor cells.
    Witzens-Harig M; Heilmann C; Hensel M; Kornacker M; Benner A; Haas R; Fruehauf S; Ho AD
    Stem Cells; 2007 Jan; 25(1):228-35. PubMed ID: 17204607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term outcome after intensive therapy with etoposide, melphalan, total body irradiation and autotransplant for acute myeloid leukemia.
    Mollee P; Gupta V; Song K; Reddy V; Califaretti N; Tsang R; Crump M; Keating A
    Bone Marrow Transplant; 2004 Jun; 33(12):1201-8. PubMed ID: 15094745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.